Discussion about Several Potential Drawbacks of PEGylated Therapeutic Proteins
-
- Zhang Fan
- Biological Engineering Institute of Zhejiang Chinese Medical University
-
- Liu Mu-rong
- BIODOOR Biotechnology Co., Ltd. of Hangzhou City in Zhejiang Province
-
- Wan Hai-tong
- Biological Engineering Institute of Zhejiang Chinese Medical University
この論文をさがす
説明
PEGylation changes the physical and chemical properties of the biomedical molecule, such as its conformation, electrostatic binding, and hydrophobicity, and results in an improvement in the pharmacokinetic behavior of the drug, while it also causes some disadvantages of which cannot be neglected. The available data manifests that polyethylene glycol (PEG) itself shows potential risk, such as immunogenicity of the PEG and PEG-containing vacuoles in cells observed with PEGylated biologicals. Decreased activity and heterogeneity are also the negative aspects of PEGylation. The unfavorable impacts which are brought by the PEGylation are described here with examples of modified therapeutic proteins on the market and used in the clinical trials.
収録刊行物
-
- Biological & Pharmaceutical Bulletin
-
Biological & Pharmaceutical Bulletin 37 (3), 335-339, 2014
公益社団法人 日本薬学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679608414720
-
- NII論文ID
- 130003382124
-
- NII書誌ID
- AA10885497
-
- COI
- 1:STN:280:DC%2BC2c3mt1CjtQ%3D%3D
-
- ISSN
- 13475215
- 09186158
-
- NDL書誌ID
- 025296049
-
- PubMed
- 24334536
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可